EXECUTIVE ENGAGEMENTS
POOL
13394
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1607
Interactions with Platform & by Email
PARTICIPANTS
402
Unique # Participated
VALIDATIONS
82
Responses Validated*
COMPANIES
18
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
202
PAGES
261
EDITION
16
PRICE
USD 5600
CODE
MCP-7443
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Orphan Drugs estimated at US$165.5 Billion in the year 2020, is projected to reach a revised size of US$371.4 Billion by 2027, growing at aCAGR of 12.2% over the period 2020-2027. Biologics, one of the segments analyzed in the report, is projected to record 11.5% CAGR and reach US$217.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Biologics segment is readjusted to a revised 13.4% CAGR for the next 7-year period.
The Orphan Drugs market in the U.S. is estimated at US$48.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$65.2 Billion by the year 2027 trailing a CAGR of 11.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.9% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.
SELECT PLAYERS
AbbVie Inc.; Actelion Pharmaceuticals Ltd.; Alexion Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca Plc.; Bayer AG; Biogen Inc.; BioMarin Pharmaceutical Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Celgene Corp.; CEL-SCI Corporation; Concordia International Corp.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Genzyme Corp.,; Johnson & Johnson; Merck & Co. Inc.; Merck Serono SA; Novartis AG; Pfizer Inc.; Recordati S.p.A.; Sanofi SA; Shire Plc.; Vertex Pharmaceuticals
SEGMENTS
» Drug Type (Biologics, Non-Biologics) » Disease Type (Oncology, Hematology, Neurology, Cardiovascular, Other Disease Types)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| A Prelude |
| Recent Market Activity |
| Increasing Adoption of Orphan Drugs by Manufacturers |
| The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry |
| Major Orphan Drugs Legislations Worldwide |
| Orphan Drugs Market on a Rapid Growth Trajectory |
| Select Major Organizations Dealing with Rare Diseases in the US, Canada, and EU |
| Incentives for Orphan Drug Designation Products in the US, EU, and Japan |
| Market Challenges |
| Obstacles for Conducting Orphan Drug Research |
| Competition |
| Orphan Drugs Remain Strong in the Pharmaceutical Pipeline |
| Important Orphan Drugs in Pipeline |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| AbbVie, Inc. (USA) |
| Actelion Pharmaceuticals Ltd. (Switzerland) |
| Alexion Pharmaceuticals, Inc. (USA) |
| Amgen, Inc. (USA) |
| AstraZeneca Plc. (UK) |
| Bayer AG (Germany) |
| Biogen Inc. (USA) |
| BioMarin Pharmaceutical Inc. (USA) |
| Boehringer Ingelheim GmbH (Germany) |
| Bristol-Myers Squibb Company (USA) |
| Celgene Corp. (USA) |
| CEL-SCI Corporation (USA) |
| Concordia International Corp. (Canada) |
| Eli Lilly and Company (USA) |
| F. Hoffmann-La Roche Ltd. (Switzerland) |
| Johnson & Johnson (USA) |
| Merck & Co., Inc. (USA) |
| Merck Serono International S.A. (Germany) |
| Merck Serono International S.A. (Germany) |
| Novartis AG (Switzerland) |
| Pfizer, Inc. (USA) |
| Recordati S.p.A. (Italy) |
| Orphan Europe (France) |
| Shire Plc. (Ireland) |
| Sanofi SA (France) |
| Genzyme Corp. (USA) |
| Vertex Pharmaceuticals (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Regulatory Incentives - A Push in the Right Direction |
| Growing Unmet Medical Needs - Fulfilling the Gap |
| Rising Incidence of Rare Forms of Cancer - Opportunities Galore |
| Select Orphan Drugs for Cancer |
| Rise in Incidence of Renal Cell Carcinoma |
| Unmet Needs in AML |
| Aging Population Offers Growth Potential |
| Pre-Symptomatic Screening to Expand Market Base |
| Asia’s Rising Awareness and Growing Population to Drive Sales |
| Drug Repurposing Provides Therapies for Rare Diseases |
| The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges |
| Interest of Major Pharmaceutical Firms Signal a Shift in Commercial Dynamics |
| Mergers and Acquisitions Drive Market Growth |
| Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016 |
| Growing Scrutiny over Skyrocketing Prices |
| Orphan Drugs with High Prices: 2016 |
| Medical Advancements Foster Growth |
| Full Reimbursements Critical for Spurring Uptake of High-Priced Orphan Drugs |
| Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs |
| Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis |
| Increasing Patient Engagement - The PAG Trend |
| Gene Therapy and Bioprocessing Preferred over Chronic Therapies |
| Companies Developing Gene Therapies |
| International Collaboration - The Way Forward |
| CNS Therapeutics to Gain Focus in the Orphan Drugs Market |
| Manufacturers Target Orphan Indications to Curtail Competition in Broader Indications |
| Manufacturers Use Orphan Disease to Target Larger Therapeutic Indications |
| Treating Autism - The Next Big Thing? |
| Sequencing Technology - The New Research Tool for Orphan Drugs |
| Innovations in Biotechnology - A Boon for Orphan Drug Research |
| Aging Gene Linked to Myeloma |
| Antibody with Potential to Treat Multiple Myeloma |
| Potential Treatment for Cystic Fibrosis Patients Infected with Mycobacterium abscessus |
| Genetic Variants to Improve Treatment of Non-small Cell Lung Cancer |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Non-Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 18 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com